Curiox Biosystems Co., Ltd (KOSDAQ: 445680)
South Korea
· Delayed Price · Currency is KRW 19,800
+50 (0.25%)
Nov 14, 2024, 9:00 AM KST
Curiox Biosystems Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 5,697 | 6,788 | 7,237 | 5,523 | 4,384 |
| Other Revenue | - | - | -0 | - | - |
| Revenue | 5,697 | 6,788 | 7,237 | 5,523 | 4,384 |
| Revenue Growth (YoY) | -33.85% | -6.21% | 31.04% | 25.97% | - |
| Cost of Revenue | 2,791 | 2,963 | 2,504 | 2,029 | 1,454 |
| Gross Profit | 2,906 | 3,825 | 4,733 | 3,494 | 2,930 |
| Selling, General & Admin | 10,916 | 10,574 | 13,217 | 10,129 | 4,930 |
| Research & Development | 2,223 | 2,109 | 1,470 | 459.64 | 172.31 |
| Other Operating Expenses | 51.45 | 51.45 | 41.27 | 23.69 | 17.49 |
| Operating Expenses | 14,957 | 14,382 | 16,154 | 11,831 | 6,197 |
| Operating Income | -12,050 | -10,557 | -11,421 | -8,337 | -3,267 |
| Interest Expense | -31.75 | -25.7 | -2,777 | -1,704 | -1,390 |
| Interest & Investment Income | 404.75 | 236.06 | 162.94 | 28.59 | 43.57 |
| Currency Exchange Gain (Loss) | 516.33 | 117.78 | 42.83 | 338.5 | -311.99 |
| Other Non Operating Income (Expenses) | 11.47 | 4.93 | 2,714 | -4,935 | -1,503 |
| EBT Excluding Unusual Items | -11,150 | -10,224 | -11,278 | -14,609 | -6,428 |
| Gain (Loss) on Sale of Assets | 0.71 | 13.02 | -12.11 | - | - |
| Asset Writedown | - | - | - | -84.1 | - |
| Pretax Income | -11,149 | -10,211 | -11,290 | -14,693 | -6,428 |
| Income Tax Expense | -243.39 | -169.26 | 207.32 | -167.52 | -148.84 |
| Earnings From Continuing Operations | -10,906 | -10,042 | -11,498 | -14,525 | -6,279 |
| Minority Interest in Earnings | 1.6 | 1.28 | 3 | 1.31 | -0.13 |
| Net Income | -10,904 | -10,040 | -11,495 | -14,524 | -6,279 |
| Net Income to Common | -10,904 | -10,040 | -11,495 | -14,524 | -6,279 |
| Shares Outstanding (Basic) | 16 | 14 | 7 | 7 | 7 |
| Shares Outstanding (Diluted) | 16 | 14 | 7 | 7 | 7 |
| Shares Change (YoY) | 80.11% | 101.31% | 8.91% | - | - |
| EPS (Basic) | -692.37 | -702.80 | -1619.76 | -2228.97 | -963.68 |
| EPS (Diluted) | -692.37 | -702.80 | -1619.76 | -2229.00 | -963.68 |
| Free Cash Flow | -9,487 | -8,376 | -10,711 | -5,387 | -2,849 |
| Free Cash Flow Per Share | -602.39 | -586.28 | -1509.32 | -826.72 | -437.27 |
| Gross Margin | 51.01% | 56.35% | 65.39% | 63.27% | 66.83% |
| Operating Margin | -211.53% | -155.53% | -157.81% | -150.95% | -74.52% |
| Profit Margin | -191.41% | -147.92% | -158.83% | -262.98% | -143.22% |
| Free Cash Flow Margin | -166.53% | -123.39% | -148.00% | -97.54% | -64.99% |
| EBITDA | -9,951 | -8,605 | -9,823 | -7,101 | -2,147 |
| EBITDA Margin | -174.68% | -126.77% | -135.73% | -128.58% | -48.98% |
| D&A For EBITDA | 2,099 | 1,952 | 1,598 | 1,236 | 1,120 |
| EBIT | -12,050 | -10,557 | -11,421 | -8,337 | -3,267 |
| EBIT Margin | -211.53% | -155.53% | -157.81% | -150.95% | -74.52% |
| Advertising Expenses | - | 775.87 | 939.61 | 397.57 | 129.69 |
Source: S&P Capital IQ. Standard template. Financial Sources.